IL256912B1 - שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול - Google Patents

שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול

Info

Publication number
IL256912B1
IL256912B1 IL256912A IL25691218A IL256912B1 IL 256912 B1 IL256912 B1 IL 256912B1 IL 256912 A IL256912 A IL 256912A IL 25691218 A IL25691218 A IL 25691218A IL 256912 B1 IL256912 B1 IL 256912B1
Authority
IL
Israel
Prior art keywords
gaboxadol
methods
developmental disorders
treating developmental
treating
Prior art date
Application number
IL256912A
Other languages
English (en)
Other versions
IL256912A (he
IL256912B2 (he
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL256912A publication Critical patent/IL256912A/he
Publication of IL256912B1 publication Critical patent/IL256912B1/he
Publication of IL256912B2 publication Critical patent/IL256912B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL256912A 2015-07-17 2016-07-14 שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול IL256912B2 (he)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (3)

Publication Number Publication Date
IL256912A IL256912A (he) 2018-03-29
IL256912B1 true IL256912B1 (he) 2023-09-01
IL256912B2 IL256912B2 (he) 2024-01-01

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
IL305342A IL305342A (he) 2015-07-17 2016-07-14 שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול
IL256912A IL256912B2 (he) 2015-07-17 2016-07-14 שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL305342A IL305342A (he) 2015-07-17 2016-07-14 שיטות לטיפול בהפרעות התפתחותיות עם גבוקסאדול

Country Status (16)

Country Link
US (8) US20170014393A1 (he)
EP (1) EP3324961A4 (he)
JP (3) JP2018520189A (he)
KR (1) KR20180031721A (he)
CN (2) CN108024997A (he)
AU (2) AU2016295138B2 (he)
BR (1) BR112018000933A2 (he)
CA (1) CA2992734A1 (he)
CL (1) CL2018000142A1 (he)
CO (1) CO2018000375A2 (he)
HK (1) HK1250951A1 (he)
IL (2) IL305342A (he)
MX (2) MX2018000745A (he)
PE (2) PE20230735A1 (he)
TW (2) TW202325293A (he)
WO (1) WO2017015049A1 (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62006B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
MX2020001342A (es) 2017-08-04 2020-08-31 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
CN112739353A (zh) * 2018-06-14 2021-04-30 奥维德医疗公司 Mir-92a或mir-145在治疗安格曼综合征中的用途
CA3110218A1 (en) * 2018-08-22 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
MX2021003302A (es) * 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
AU2019384561A1 (en) * 2018-11-21 2021-06-10 Certego Therapeutics Inc. Combination of gaboxadol and lithium for the treatment of psychiatric disorders
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
WO2020247127A1 (en) * 2019-06-07 2020-12-10 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제
CN114786669A (zh) * 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
IL298334A (he) 2020-05-20 2023-01-01 Certego Therapeutics Inc טבעת גבוקסאדול מבוטלת והשימוש בה לטיפול בהפרעות פסיכיאטריות

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
KR20070010136A (ko) * 2004-04-02 2007-01-22 하. 룬트벡 아크티에 셀스카브 가복사돌을 이용한 손상된 호흡 기능의 치료
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
HUE032743T2 (en) * 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
EP2621282B1 (en) 2010-09-28 2020-04-15 The Regents of The University of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
EP2765989B1 (en) 2011-10-13 2016-04-13 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
RS62006B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
WO2015189744A1 (en) 2014-06-12 2015-12-17 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US20180235942A1 (en) 2015-08-11 2018-08-23 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EIXOTO M F ET AL,, EFFECTS OF GABAERGIC DRUGS ON RESERPINE-INDUCED ORAL DYSKINESIA, 7 May 2005 (2005-05-07) *
GUNVANT K. THAKER,, BRAIN [GAMMA]-AMINOBUTYRIC ACID ABNORMALITY IN TARDIVE DYSKINESIA : REDUCTION IN CEREBROSPINAL FLUID GABA LEVELS AND THERAPEUTIC RESPONSE TO GABA AGONIST TREATMENT, 1 June 1987 (1987-06-01) *
K. EGAWA ET AL, DECREASED TONIC INHIBITION IN CEREBELLAR GRANULE CELLS CAUSES MOTOR DYSFUNCTION IN A MOUSE MODEL OF ANGELMAN SYNDROME, 5 December 2012 (2012-12-05) *
LOZANO REYMUNDO ET AL,, MODULATION OF THE GABAERGIC PATHWAY FOR THE TREATMENT OF FRAGILE X SYNDROME, 1 January 2014 (2014-01-01) *
OLMOS-SERRANO J. L. ET AL.,, THE GABA(A) RECEPTOR AGONIST THIP AMELIORATES SPECIFIC BEHAVIORAL DEFICITS IN THE MOUSE MODEL OF FRAGILE X SYNDROME, 31 December 2011 (2011-12-31) *

Also Published As

Publication number Publication date
AU2016295138A1 (en) 2018-02-08
AU2016295138B2 (en) 2021-11-04
MX2018000745A (es) 2018-08-15
EP3324961A1 (en) 2018-05-30
IL305342A (he) 2023-10-01
TWI819995B (zh) 2023-11-01
CN116531370A (zh) 2023-08-04
IL256912A (he) 2018-03-29
US20190321342A1 (en) 2019-10-24
BR112018000933A2 (pt) 2018-09-04
AU2021250862A1 (en) 2021-11-04
CN108024997A (zh) 2018-05-11
MX2022004734A (es) 2022-05-13
WO2017015049A1 (en) 2017-01-26
US20210030727A1 (en) 2021-02-04
EP3324961A4 (en) 2019-03-13
CA2992734A1 (en) 2017-01-26
US20230071127A1 (en) 2023-03-09
TW202325293A (zh) 2023-07-01
PE20230735A1 (es) 2023-05-03
KR20180031721A (ko) 2018-03-28
US20180098974A1 (en) 2018-04-12
CL2018000142A1 (es) 2018-07-13
US20180338960A1 (en) 2018-11-29
US20190255027A1 (en) 2019-08-22
HK1250951A1 (zh) 2019-01-18
IL256912B2 (he) 2024-01-01
JP2021130687A (ja) 2021-09-09
PE20190338A1 (es) 2019-03-07
US20170014393A1 (en) 2017-01-19
JP2018520189A (ja) 2018-07-26
JP2023103375A (ja) 2023-07-26
US11096929B2 (en) 2021-08-24
US20190117632A1 (en) 2019-04-25
AU2021250862B2 (en) 2023-11-09
CO2018000375A2 (es) 2018-04-19
TW201707700A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
HK1250951A1 (zh) 用加波沙朵治療發育障礙的方法
IL285151A (he) שיטות לטיפול בהפרעות קשורות ל– fgf21
IL266770A (he) שיטות לטיפול במצבים דלקתיים
IL282655A (he) שיטות לטיפול בהפרעות התפתחותיות באמצעות פיפראדרול
EP3359171C0 (en) USING AKKERMANSIA MUCINIPHILA TO TREAT INFLAMMATORY CONDITIONS
GB201701673D0 (en) Methods of well treatment
HK1248552A1 (zh) 使用川地匹坦的治療方法
IL252296A0 (he) שיטות לטיפול בטרשת נפוצה
IL290069A (he) שיטות לטיפול במצבי עיניים
EP3484452A4 (en) METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES
HK1246655A1 (zh) 治療不育的方法
HK1259347A1 (zh) 治療結腸炎的方法
IL272092A (he) שיטות לטיפול בשינויים בהתנהגות
GB201416832D0 (en) Methods of treatment
IL251769A0 (he) שיטות לטיפול במצבים עיניים
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
HK1244692A1 (zh) 治療纖維化的方法
IL265568A (he) שיטות לטיפול בהרמת tim-3
HK1243937A1 (zh) 治療疾病的方法
ZA201607068B (en) Methods for treating hypersomnia
GB201512139D0 (en) Methods of treatment
PT3261661T (pt) Menotropina para tratar a infertilidade
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders